https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
4% vs 40.3%; P.001). The PPRF strategy implemented by the AST could improve the carbapenem usage by increasing the DE rate of carbapenem. The PPRF strategy implemented by the AST could improve the carbapenem usage by increasing the DE rate of carbapenem. We compared the new use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) versus dipeptidyl peptidase-4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD), in patients with type 2 diabetes without a history of pre
Like
Comment
Share
